CN103565790A - Application of formononetin in cryptococcus neoformans - Google Patents
Application of formononetin in cryptococcus neoformans Download PDFInfo
- Publication number
- CN103565790A CN103565790A CN201310550449.0A CN201310550449A CN103565790A CN 103565790 A CN103565790 A CN 103565790A CN 201310550449 A CN201310550449 A CN 201310550449A CN 103565790 A CN103565790 A CN 103565790A
- Authority
- CN
- China
- Prior art keywords
- formononetin
- antifungal
- application
- cryptococcus neoformans
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of formononetin in cryptococcus neoformans. The technical scheme of the invention is the application of formononetin in preparing medicaments for treating antifungal infected diseases, wherein the fungus is cryptococcus neoformans. The compound has an excellent antifungal activity on various superficial and deep funguses, has the advantages of high activity, low toxicity, broad antifungal spectrum and the like when being compared with an antifungal medicament in existing clinical application, and can be used for preparing antifungal medicaments.
Description
Technical field
The present invention relates to a kind of compound application, specifically, is in neogenesis cryptococcus purposes about formoononetin.
Background technology
The position that fungal infectious disease is invaded human body according to fungus is divided into 4 classes: superficial fungi disease, dermatomycosis, subcutaneous mycosis and systemic mycoses; The former two is collectively referred to as superficial mycosis, and the latter two are called again deep mycosis.Fungal infectious disease is divided into following several according to fungal infection difference: candida albicans bacterium infectious disease, Candida parapsilosis bacterium infectious disease, Candida glabrata infectious disease, infection by Cryptococcus neoformans disease, Gypsum Fibrosum shape sporidiole bacteria infectious disease, trichophyton infectious disease, aspergillus fumigatus infection disease.
In recent years, extensive use along with broad ectrum antibiotic, corticosteroid and immunosuppressant, advanced Clinics is as the popularization of organ transplantation etc., AIDS's is popular, and the impact of tumor Radiotherapy chemotherapy, cause fungal infection particularly deep fungal infection significantly rise, deep fungal infection has now become the major disease main causes of death such as acquired immune deficiency syndrome (AIDS) and tumor.
Reported at present and clinically conventional nitrogen azole compounds have ketoconazole (Ketoconazole, KCZ), fluconazol (Fluconazole, FCZ), voriconazole (Voriconazole, VCZ), itraconazole (Itraconazole, ICZ), amphotericin B (Amphotericin B, AMB) etc., but these compounds still exist, and above-mentioned toxic and side effects is large, narrow antimicrobial spectrum, easily produce the defects such as drug resistance, for example bring into play the required dosage of drug effect larger, thereby can produce larger toxic and side effects to human body.
Formononetin (Formononetin), has another name called formoononetin, is a kind of Isoflavone compounds, comes from inflorescence and the wounded in the battle branch and leaf of leguminous plant Herba Trifolii Pratentis (Trifolium Pratense L).Its molecular formula is C
16h
12o
4, molecular weight is 268.26.Research shows, formononetin has blood lipid metabolism in control agent, suppresses the pharmacological activities such as the atherosis and estrogen-like effects of Liver fatty deposition and prevention of arterial.But in infectious disease application, have no report about formononetin.
Summary of the invention
The object of the invention is for deficiency of the prior art, provide a kind of formoononetin in neogenesis cryptococcus purposes.
For achieving the above object, the technical scheme that the present invention takes is: the application of a kind of formoononetin in preparing fungal infectious disease medicine, described fungus is neogenesis cryptococcus.
The invention has the advantages that: compound of the present invention has good antifungal activity to various superficial parts and deep fungal, compare with the antifungal drug of existing clinical practice to there is the advantages such as efficient, hypotoxicity, anti-fungus spectra be wide, can be used for preparing antifungal drug.
The specific embodiment
Below the specific embodiment provided by the invention is elaborated.
Embodiment 1
Below the specific embodiment provided by the invention is elaborated.
(1) experimental technique: adopt conventional In Vitro Bacteriostasis experimental technique (to refer to: Antimicrob Agents Chemother 1995,39 (5): 1169)
1. materials and methods
(1) testing compound of the present invention: formononetin has another name called formoononetin (Formononetin), its molecular formula is C
16h
12o
4, molecular weight is 268.26.
Experimental strain is as follows:
This experiment has selected following 8 kinds of common human body cause illness's standard fungal bacterial strains as screening object:
(2) test method
Bacteria suspension preparation: above-mentioned fungus is cultivated 16 hours through 35 ℃ of YEPD fluid mediums, twice activation, with blood cell counting plate counting, adjusts bacteria concentration to 1 * 10 with RPM1640 fluid medium
4～1 * 10
5individual/mL.
Medicinal liquid preparation: get testing compound of the present invention and be dissolved in dimethyl sulfoxine, be made into the medicine storage liquid of 8.0mg/mL, be diluted to 640 μ g/mL with RPM1640 before experiment.
Inoculation: get drug sensitive plate, add RPMI RPMI-1640 200 μ l in No. 1 hole of every row, make blank; No. 12 hole adds bacterium liquid 200 μ l to be measured, makes negative control; 2 ~ No. 11 holes of the every row of drug sensitive plate add respectively bacterium liquid 180 μ l, fully mix, and make the final drug level in each hole be respectively 64,32,16,8,4,2,1,0.5,0.25 and 0.125 μ g/ml, and in each hole, DMSO content is all lower than 1%; Positive control, not containing medicine, is made in No. 12 holes.Control drug is fluconazol (FCZ), itraconazole (ICZ), voriconazole (VCZ), ketoconazole (KCZ), terbinafine (TBR), amphotericin B (AMB).
Cultivate and detect: establishing positive control hole optical density value (OD value) is 100%, the optical density value of take is minimal inhibitory concentration value (MIC than positive control hole lower than 80% lowest drug concentration
80).
(2) experimental result
In Vitro Bacteriostasis experimental result is in Table 2.
Note: KCZ. ketoconazole, FCZ. fluconazol, VCZ. Wo Likang azoles, ICZ. itraconazole, TRB. terbinafine, AMB amphotericin
Above-mentioned experimental result shows that compound of the present invention has good antifungal activity, and compound is all far better than fluconazol to the vitro inhibition activity of selected fungus, illustrates that the compounds of this invention can be used for preparing the medicine of anti-fungal infection.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of the inventive method; can also make some improvement and supplement, these improvement and supplement and also should be considered as protection scope of the present invention.
Claims (1)
1. the application of formoononetin in preparing fungal infectious disease medicine, described fungus is neogenesis cryptococcus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310550449.0A CN103565790A (en) | 2013-11-08 | 2013-11-08 | Application of formononetin in cryptococcus neoformans |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310550449.0A CN103565790A (en) | 2013-11-08 | 2013-11-08 | Application of formononetin in cryptococcus neoformans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103565790A true CN103565790A (en) | 2014-02-12 |
Family
ID=50039073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310550449.0A Pending CN103565790A (en) | 2013-11-08 | 2013-11-08 | Application of formononetin in cryptococcus neoformans |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103565790A (en) |
-
2013
- 2013-11-08 CN CN201310550449.0A patent/CN103565790A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 邓丽: "甘草渣中黄酮类化合物的提取纯化、分离鉴定及其抑菌活性研究", 《中国优秀硕士学位论文全文数据库 工程科技Ι辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jia et al. | Silver nanoparticles offer a synergistic effect with fluconazole against fluconazole-resistant Candida albicans by abrogating drug efflux pumps and increasing endogenous ROS | |
| EP1867332B1 (en) | Pharmaceutical composition and method using antifungal agent in combination | |
| CN103536613B (en) | A kind of antifungal pharmaceutical composition | |
| CN105193808A (en) | Synergistic drug effect of combination of BDSF and itraconazole on clinical drug-resistant candida albicans | |
| CN110769854B (en) | Antifungal agents for use in combination | |
| WO2014115487A1 (en) | Pharmaceutical composition for diseases caused by pathogenic microorganisms such as aspergillus | |
| CN107812011B (en) | Antifungal pharmaceutical composition | |
| Cong et al. | In vitro activity of berberine alone and in combination with antifungal drugs against planktonic forms and biofilms of Trichosporon asahii | |
| CN103565794A (en) | Application of 7-hydroxy-4'-methoxyisoflavone in antifungal medicament | |
| CN103585143A (en) | Application of formononetin in preparation of aspergillus fumigatus resistant medicament | |
| Jiang et al. | In vitro interactions of antifungal agents and everolimus against Aspergillus species | |
| CN103565790A (en) | Application of formononetin in cryptococcus neoformans | |
| CN103565795A (en) | Application of formononetin in antifungal medicaments | |
| CN103565793A (en) | Application of formononetin in antifungal medicaments | |
| CN103565791A (en) | Application of formononetin in trichophyton rubrum | |
| CN103565792A (en) | Application of formononetin in microsporum gypseum | |
| CN103356626B (en) | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases | |
| CN103417545B (en) | Application of pyrazolopyrimidine compound in preparing medicines for aspergillus fumigatus infectious diseases | |
| CN103356624B (en) | Use of pyrimidine compound in antifungal drugs | |
| CN103356627B (en) | Use of drug in treatment on candida glabrata infected diseases | |
| CN103356628B (en) | Use of pyrazolopyrimidine compound in pharmacy | |
| CN103405439B (en) | Application of pyrimidine compound to preparing antifungal medicines | |
| CN103356625B (en) | Use of pyrazolopyrimidine compound in treatment on candida parapsilosis infected diseases | |
| CN106580999A (en) | Application of JNK inhibitor in preparing drug | |
| An et al. | Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140212 |